Literature DB >> 25053982

Beta blockers: an innovation in the treatment of infantile hemangiomas.

Shehla Admani1, Stephanie Feldstein1, Ernesto M Gonzalez2, Sheila Fallon Friedlander1.   

Abstract

Infantile hemangiomas are benign vascular tumors seen in 4.5 percent of neonates and infants. While most infantile hemangiomas can be managed with active nonintervention, a subset of patients will require more aggressive management. Here the authors review the use of beta-blockers in the treatment of infantile hemangiomas, including oral, topical, and multimodal treatment options. They discuss the latest data on propranolol, including criteria for patient selection, dosing recommendations, and appropriate monitoring for side effects and efficacy. Lastly, they review indications for topical timolol treatment and the potential benefits of concomitant laser therapy.

Entities:  

Year:  2014        PMID: 25053982      PMCID: PMC4106356     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  48 in total

1.  Propranolol for severe hemangiomas of infancy.

Authors:  Christine Léauté-Labrèze; Eric Dumas de la Roque; Thomas Hubiche; Franck Boralevi; Jean-Benoît Thambo; Alain Taïeb
Journal:  N Engl J Med       Date:  2008-06-12       Impact factor: 91.245

2.  Late rebound of infantile hemangioma after cessation of oral propranolol.

Authors:  Nancy Shehata; Julie Powell; Josée Dubois; Afshin Hatami; Elizabeth Rousseau; Sandra Ondrejchak; Catherine McCuaig
Journal:  Pediatr Dermatol       Date:  2013 Sep-Oct       Impact factor: 1.588

3.  Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis.

Authors:  Juliette Mazereeuw-Hautier; Peter H Hoeger; Sarah Benlahrech; Amir Ammour; Pierre Broue; Julie Vial; Gerard Ohanessian; Christine Léauté-Labrèze; Marc Labenne; Pierre Vabres; Jochen Rössler; Christine Bodemer
Journal:  J Pediatr       Date:  2010-05-20       Impact factor: 4.406

4.  Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment.

Authors:  Anita N Haggstrom; Beth A Drolet; Eulalia Baselga; Sarah L Chamlin; Maria C Garzon; Kimberly A Horii; Anne W Lucky; Anthony J Mancini; Denise W Metry; Brandon Newell; Amy J Nopper; Ilona J Frieden
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

5.  A randomized controlled trial of propranolol for infantile hemangiomas.

Authors:  Marcia Hogeling; Susan Adams; Orli Wargon
Journal:  Pediatrics       Date:  2011-07-25       Impact factor: 7.124

6.  [Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations].

Authors:  I Sánchez-Carpintero; R Ruiz-Rodriguez; J C López-Gutiérrez
Journal:  Actas Dermosifiliogr       Date:  2011-07-19

7.  Propranolol for hemangiomas.

Authors:  Mahmudul Hasan; Matiur Rahman; Shafiqul Hoque; A K M Zahid Hossain; Lubna Khondker
Journal:  Pediatr Surg Int       Date:  2012-12-18       Impact factor: 1.827

8.  Consensus Statement on Diagnostic Criteria for PHACE Syndrome.

Authors:  Denise Metry; Geoffrey Heyer; Christopher Hess; Maria Garzon; Anita Haggstrom; Peter Frommelt; Denise Adams; Dawn Siegel; Karla Hall; Julie Powell; Ilona Frieden; Beth Drolet
Journal:  Pediatrics       Date:  2009-10-26       Impact factor: 7.124

9.  Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.

Authors:  Harvey Chim; Bryan S Armijo; Erin Miller; Christy Gliniak; Marc A Serret; Arun K Gosain
Journal:  Ann Surg       Date:  2012-07       Impact factor: 12.969

10.  Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies.

Authors:  A Munden; R Butschek; W L Tom; J S Marshall; D M Poeltler; S E Krohne; A B Alió; M Ritter; D F Friedlander; V Catanzarite; A Mendoza; L Smith; M Friedlander; S F Friedlander
Journal:  Br J Dermatol       Date:  2014-04       Impact factor: 9.302

View more
  3 in total

Review 1.  β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of β3 -adrenoceptors.

Authors:  Massimo Dal Monte; Maura Calvani; Maurizio Cammalleri; Claudio Favre; Luca Filippi; Paola Bagnoli
Journal:  Br J Pharmacol       Date:  2018-12-18       Impact factor: 8.739

2.  Angiolymphoid Hyperplasia with Eosinophilia and its Response to the Combination of Radiofrequency Ablation and Topical Timolol.

Authors:  Pooja Arora; Neha Meena; Prafulla K Sharma; Minakshi Bhardwaj
Journal:  Indian Dermatol Online J       Date:  2017 Jul-Aug

3.  Beta-adrenergic antagonist for the healing of chronic diabetic foot ulcers: study protocol for a prospective, randomized, double-blinded, controlled and parallel-group study.

Authors:  Ramanjot Kaur; Catherine Tchanque-Fossuo; Kaitlyn West; Yasmin Hadian; Anthony Gallegos; Daniel Yoon; Ligia Ismailyan; Saul Schaefer; Sara E Dahle; R Rivkah Isseroff
Journal:  Trials       Date:  2020-06-08       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.